Profile data is unavailable for this security.
About the company
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
- Revenue in USD (TTM)0.00
- Net income in USD-127.27m
- Incorporated2017
- Employees110.00
- LocationBiomea Fusion Inc900 Middlefield Road, 4Th FloorREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 980-9099
- Fax+1 (302) 655-5049
- Websitehttps://www.biomeafusion.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aura Biosciences Inc | 0.00 | -78.65m | 370.09m | 88.00 | -- | 1.77 | -- | -- | -1.86 | -1.86 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -35.66 | -- | -37.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
Verrica Pharmaceuticals Inc | 8.91m | -80.74m | 372.45m | 100.00 | -- | 246.98 | -- | 41.79 | -1.75 | -1.75 | 0.1929 | 0.0356 | 0.1321 | -- | 2.33 | 89,130.00 | -119.66 | -55.75 | -142.98 | -78.33 | 79.63 | -- | -905.83 | -754.94 | 3.04 | -21.71 | 0.9678 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
Jasper Therapeutics Inc | 0.00 | -63.93m | 383.32m | 45.00 | -- | 3.39 | -- | -- | -5.60 | -5.60 | 0.00 | 7.51 | 0.00 | -- | -- | 0.00 | -48.30 | -- | -51.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
Lenz Therapeutics Inc | 0.00 | -117.37m | 384.04m | 6.00 | -- | 1.94 | -- | -- | -15.88 | -15.88 | 0.00 | 7.77 | 0.00 | -- | -- | 0.00 | -44.51 | -- | -47.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Anika Therapeutics Inc | 169.26m | -76.83m | 389.10m | 357.00 | -- | 1.86 | -- | 2.30 | -5.24 | -5.24 | 11.54 | 14.07 | 0.5616 | 1.42 | 5.40 | 474,120.40 | -25.49 | -5.41 | -28.16 | -5.87 | 61.96 | 60.70 | -45.39 | -12.60 | 3.85 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
Biomea Fusion Inc | 0.00 | -127.27m | 405.10m | 110.00 | -- | 2.99 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
Contineum Therapeutics Inc | 50.00m | 19.13m | 414.66m | 31.00 | 21.18 | -- | 21.43 | 8.29 | 0.7611 | 0.7611 | 1.99 | 4.66 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 38.25 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
Korro Bio Inc | 0.00 | -81.19m | 414.87m | 94.00 | -- | 2.37 | -- | -- | -43.16 | -43.16 | 0.00 | 18.87 | 0.00 | -- | -- | 0.00 | -54.22 | -31.55 | -60.95 | -36.48 | -- | -- | -- | -365.87 | -- | -357.64 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
ACELYRIN Inc | 0.00 | -240.16m | 420.86m | 130.00 | -- | 0.6523 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
Alector Inc | 96.41m | -120.61m | 421.20m | 244.00 | -- | 2.35 | -- | 4.37 | -1.39 | -1.39 | 1.12 | 1.86 | 0.1393 | -- | -- | 395,106.60 | -17.43 | -20.00 | -21.55 | -23.81 | -- | -- | -125.11 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
Precigen Inc | 5.44m | -96.91m | 431.64m | 202.00 | -- | 4.41 | -- | 79.36 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
Theravance Biopharma Inc | 61.51m | -44.77m | 431.86m | 99.00 | -- | 2.11 | -- | 7.02 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Fate Therapeutics Inc | 6.48m | -190.05m | 432.56m | 181.00 | -- | 1.01 | -- | 66.77 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
Replimune Group Inc | 0.00 | -215.79m | 436.66m | 331.00 | -- | 1.17 | -- | -- | -3.24 | -3.24 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -38.05 | -29.08 | -40.71 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1593 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
Verve Therapeutics Inc | 16.05m | -196.83m | 443.34m | 255.00 | -- | 0.759 | -- | 27.62 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Ocugen Inc | 7.05m | -58.50m | 445.22m | 65.00 | -- | 14.71 | -- | 63.15 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.36m | 14.92% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.49m | 12.50% |
Cormorant Asset Management LPas of 31 Mar 2024 | 3.57m | 9.95% |
Laurion Capital Management LPas of 31 Mar 2024 | 2.72m | 7.58% |
Baker Bros. Advisors LPas of 31 Mar 2024 | 2.11m | 5.88% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.66m | 4.63% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.31m | 3.65% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.27m | 3.54% |
Driehaus Capital Management LLCas of 31 Mar 2024 | 1.19m | 3.33% |
Aisling Capital Management LPas of 31 Mar 2024 | 798.76k | 2.23% |